Single-domain antibodies as potent inhibitors of clinically relevant β-lactamases in multidrug-resistant bacteria
Frontiers in Microbiology · 10.06.2026 · 17
DOI: 10.3389/fmicb.2026.1840552 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 10.06.2026. Verfasst von Paloma Osset-Trenor und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación e Innovación en Bioingeniería Ci2B, Universitat Politècnica de València, Ciudad Politécnica de la Innovación, Valencia, Spain. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antimicrobial resistance (AMR) represents a critical threat to global health, largely driven by the dissemination of β -lactamases that inactivate frontline antibiotics. Among the most problematic are BlaMab-2 from Mycobacterium abscessus , KPC-2 and OXA-48 from Klebsiella pneumoniae , and VIM-2 from Pseudomonas aeruginosa , which together confer broad resistance to β -lactams and carbapenems. Current β -lactamase inhibitors face declining efficacy as resistance variants continue to emerge, underscoring the need for innovative strategies. Here, we explored single-domain antibodies (sd-Abs) as enzyme-directed inhibitors of β -lactamases. A library of sd-Abs was screened, and two candidates, B2 and B5, were characterized in vitro and cell-based assays. Both sd-Abs inhibited BlaMab-2 activity in E. coli expression systems, following a competitive inhibition mechanism, with B2 consistently displaying stronger potency (K i ≈ 1.5 μM) than B5. Remarkably, B2 also demonstrated broad inhibitory activity against KPC-2, VIM-2, and OXA-48, while B5 showed an alternative inhibition profile, including uncompetitive characteristics against VIM-2 and OXA-48. Comparison with clinically deployed inhibitors revealed that the K i values of B2 and B5 are of the same order of magnitude, or superior in some cases, highlighting their therapeutic promise. Our findings establish sd-Abs as a versatile platform for the inhibition of diverse β -lactamases, with B2 emerging as the most broadly effective candidate. By expanding the utility of existing β -lactams, sd-Abs could help restore antibiotic efficacy against multidrug-resistant pathogens. This study underscores the potential of antibody-based enzyme inhibitors as a new class of anti-resistance therapeutics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centro de Investigación e Innovación en Bioingeniería Ci2B, Universitat Politècnica de València, Ciudad Politécnica de la Innovación, Valencia, Spain.
- Department of Metabolism, Inflammation and Aging, Instituto de Biomedicina de Valencia IBV-CSIC, Valencia, Spain.
- Valencia Biomedical Research Foundation, Centro de Investigación Príncipe Felipe (CIPF) - Associated Unit to the Instituto de Biomedicina de Valencia IBV-CSIC, Valencia, Spain.
Zitieren
APA
Osset-Trenor, P., Proft, M., & Pascual-Ahuir, A. (2026). Single-domain antibodies as potent inhibitors of clinically relevant β-lactamases in multidrug-resistant bacteria. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1840552
Vancouver
Osset-Trenor P, Proft M, Pascual-Ahuir A. Single-domain antibodies as potent inhibitors of clinically relevant β-lactamases in multidrug-resistant bacteria. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1840552
BibTeX
@article{OssetTrenor2026,
author = {Osset-Trenor, Paloma and Proft, Markus and Pascual-Ahuir, Amparo},
title = {Single-domain antibodies as potent inhibitors of clinically relevant β-lactamases in multidrug-resistant bacteria},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1840552}
}
EUVIMED